1-800-526-8630
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 6
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
- MORE
About Cystic Fibrosis Therapeutics
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.
The analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Key vendors
READ MORE
CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein.
The analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Key vendors
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
- Improved diagnostic technologies
- For a full, detailed list, view the full report
- Drug discontinuation
- For a full, detailed list, view the full report
- Strategic collaborations
- For a full, detailed list, view the full report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
Note: Product cover images may vary from those shown
2 of 6
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 10: REGIONAL LANDSCAPE
PART 12: DRIVERS AND CHALLENGES
Exhibit 01: Autosomal recessive pattern of inheritance in CF
Exhibit 02: Effects of CF on different body parts
Exhibit 03: Most common CFTR mutations
Exhibit 04: Global birth prevalence of CF by 2017
Exhibit 05: Diagnosis and treatment of CF
Exhibit 06: Parent market
Exhibit 07: Market characteristics
Exhibit 08: Market segments
Exhibit 09: Market definition: Inclusions and exclusions checklist
Exhibit 10: Market size
Exhibit 11: Validation techniques employed for market sizing 2017
Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions)
Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Bargaining power of suppliers
Exhibit 18: Threat of new entrants
Exhibit 19: Threat of substitutes
Exhibit 20: Threat of rivalry
Exhibit 21: Market condition: Five forces 2017
Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share)
Exhibit 23: Comparison by drug class
Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions)
Exhibit 25: KALYDECO description
Exhibit 26: ORKAMBI description
Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%)
Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions)
Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%)
Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions)
Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%)
Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions)
Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%)
Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions)
Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%)
Exhibit 36: Market opportunity by drug class
Exhibit 37: Customer landscape
Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share)
Exhibit 39: Regional comparison
Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%)
Exhibit 42: Top three countries in Americas
Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 45: Top three countries in EMEA
Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%)
Exhibit 48: Top three countries in APAC
Exhibit 49: Market opportunity
Exhibit 50: Few drugs with breakthrough therapy designation for CF
Exhibit 51: Few drugs with Orphan Drug Designation for CF
Exhibit 52: Few CF therapeutics discontinued from development
Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics
Exhibit 54: Vendor landscape
Exhibit 55: Landscape disruption
Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017
Exhibit 57: Vendors covered
Exhibit 58: Vendor classification
Exhibit 59: Market positioning of vendors
Exhibit 60: AbbVie: Overview
Exhibit 61: AbbVie: Business segments
Exhibit 62: AbbVie: Organizational developments
Exhibit 63: AbbVie: Geographic focus
Exhibit 64: AbbVie: Segment focus
Exhibit 65: AbbVie: Key offerings
Exhibit 66: AbbVie: Key customers
Exhibit 67: Gilead: Overview
Exhibit 68: Gilead: Business segments
Exhibit 69: Gilead: Organizational developments
Exhibit 70: Gilead: Geographic focus
Exhibit 71: Gilead: Segment focus
Exhibit 72: Gilead: Key offerings
Exhibit 73: Gilead: Key customers
Exhibit 74: F. Hoffmann-La Roche: Overview
Exhibit 75: F. Hoffmann-La Roche: Business segments
Exhibit 76: F. Hoffmann-La Roche: Organizational developments
Exhibit 77: F. Hoffmann-La Roche: Geographic focus
Exhibit 78: F. Hoffmann-La Roche: Segment focus
Exhibit 79: F. Hoffmann-La Roche: Key offerings
Exhibit 80: F. Hoffmann-La Roche: Key customers
Exhibit 81: Vertex Pharmaceuticals: Overview
Exhibit 82: Vertex Pharmaceuticals: Business segments
Exhibit 83: Vertex Pharmaceuticals: Organizational developments
Exhibit 84: Vertex Pharmaceuticals: Geographic focus
Exhibit 85: Vertex Pharmaceuticals: Segment focus
Exhibit 86: Vertex Pharmaceuticals: Key offerings
Exhibit 87: Vertex Pharmaceuticals: Key customers
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Market outline
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing
- Market size and forecast
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Comparison by drug class
- CFTR modulators
- Mucolytics
- PERT
- Anti-infectives
- Bronchodilators
- Market opportunity by drug class
PART 10: REGIONAL LANDSCAPE
- Regional comparison
- CF therapeutics market in Americas
- CF therapeutics market in EMEA
- CF therapeutics market in APAC
- Market opportunity
PART 12: DRIVERS AND CHALLENGES
- Market Drivers
- Market challenges
- Strategic collaborations
- Advances in technology for drug development and delivery
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
- List of abbreviations
Exhibit 01: Autosomal recessive pattern of inheritance in CF
Exhibit 02: Effects of CF on different body parts
Exhibit 03: Most common CFTR mutations
Exhibit 04: Global birth prevalence of CF by 2017
Exhibit 05: Diagnosis and treatment of CF
Exhibit 06: Parent market
Exhibit 07: Market characteristics
Exhibit 08: Market segments
Exhibit 09: Market definition: Inclusions and exclusions checklist
Exhibit 10: Market size
Exhibit 11: Validation techniques employed for market sizing 2017
Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions)
Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Bargaining power of suppliers
Exhibit 18: Threat of new entrants
Exhibit 19: Threat of substitutes
Exhibit 20: Threat of rivalry
Exhibit 21: Market condition: Five forces 2017
Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share)
Exhibit 23: Comparison by drug class
Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions)
Exhibit 25: KALYDECO description
Exhibit 26: ORKAMBI description
Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%)
Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions)
Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%)
Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions)
Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%)
Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions)
Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%)
Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions)
Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%)
Exhibit 36: Market opportunity by drug class
Exhibit 37: Customer landscape
Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share)
Exhibit 39: Regional comparison
Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%)
Exhibit 42: Top three countries in Americas
Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%)
Exhibit 45: Top three countries in EMEA
Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%)
Exhibit 48: Top three countries in APAC
Exhibit 49: Market opportunity
Exhibit 50: Few drugs with breakthrough therapy designation for CF
Exhibit 51: Few drugs with Orphan Drug Designation for CF
Exhibit 52: Few CF therapeutics discontinued from development
Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics
Exhibit 54: Vendor landscape
Exhibit 55: Landscape disruption
Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017
Exhibit 57: Vendors covered
Exhibit 58: Vendor classification
Exhibit 59: Market positioning of vendors
Exhibit 60: AbbVie: Overview
Exhibit 61: AbbVie: Business segments
Exhibit 62: AbbVie: Organizational developments
Exhibit 63: AbbVie: Geographic focus
Exhibit 64: AbbVie: Segment focus
Exhibit 65: AbbVie: Key offerings
Exhibit 66: AbbVie: Key customers
Exhibit 67: Gilead: Overview
Exhibit 68: Gilead: Business segments
Exhibit 69: Gilead: Organizational developments
Exhibit 70: Gilead: Geographic focus
Exhibit 71: Gilead: Segment focus
Exhibit 72: Gilead: Key offerings
Exhibit 73: Gilead: Key customers
Exhibit 74: F. Hoffmann-La Roche: Overview
Exhibit 75: F. Hoffmann-La Roche: Business segments
Exhibit 76: F. Hoffmann-La Roche: Organizational developments
Exhibit 77: F. Hoffmann-La Roche: Geographic focus
Exhibit 78: F. Hoffmann-La Roche: Segment focus
Exhibit 79: F. Hoffmann-La Roche: Key offerings
Exhibit 80: F. Hoffmann-La Roche: Key customers
Exhibit 81: Vertex Pharmaceuticals: Overview
Exhibit 82: Vertex Pharmaceuticals: Business segments
Exhibit 83: Vertex Pharmaceuticals: Organizational developments
Exhibit 84: Vertex Pharmaceuticals: Geographic focus
Exhibit 85: Vertex Pharmaceuticals: Segment focus
Exhibit 86: Vertex Pharmaceuticals: Key offerings
Exhibit 87: Vertex Pharmaceuticals: Key customers
Note: Product cover images may vary from those shown
3 of 6
LOADING...
4 of 6
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Vertex Pharmaceuticals
- MORE
New Report Released: - Global Cystic Fibrosis Therapeutics Market 2018-2022
The author of the report recognizes the following companies as the key players in the global cystic fibrosis therapeutics market: AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “One trend in the market is strategic collaborations. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the efficacy of products has already been demonstrated, thereby cutting down on initial R&D expenditure.”
According to the report, one driver in the market is improved diagnostic technologies. CF is a genetically inherited disease. Several diagnostic tests are available to detect the disease. Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests. Growing investment in and awareness about genetic diseases are expected to lead to improved diagnostic technologies, which will drive the growth of the market.
Further, the report states that one challenge in the market is drug discontinuation. Discontinuation of drugs from the development stage or from the market after their launch is a major challenge for investors and drug manufacturers. The discontinuation of drugs from the late-stage development or after approval due to reasons such as safety concerns leads to a significant financial loss for investors because of the high R&D and marketing costs involved in the process of drug development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global cystic fibrosis therapeutics market: AbbVie, Gilead, F. Hoffmann-La Roche, and Vertex Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “One trend in the market is strategic collaborations. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the efficacy of products has already been demonstrated, thereby cutting down on initial R&D expenditure.”
According to the report, one driver in the market is improved diagnostic technologies. CF is a genetically inherited disease. Several diagnostic tests are available to detect the disease. Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests. Growing investment in and awareness about genetic diseases are expected to lead to improved diagnostic technologies, which will drive the growth of the market.
Further, the report states that one challenge in the market is drug discontinuation. Discontinuation of drugs from the development stage or from the market after their launch is a major challenge for investors and drug manufacturers. The discontinuation of drugs from the late-stage development or after approval due to reasons such as safety concerns leads to a significant financial loss for investors because of the high R&D and marketing costs involved in the process of drug development.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 6
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
